Clinical Trial Update: 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for 506U78 in relapsed or refractory acute lymphoblastic leukemia (T-ALL) and T-NHL (lymphoblastic).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• 506U78

Snippet

Sponsor: Goethe University | Conditions: T-ALL, T-NHL (Lymphoblastic) | Phase 2 | Status: COMPLETED